Founded in 2020, PCA Rx provides claims processing, consultations, customized clinical services, data reporting and collection, key performance indicator analysis, and rebate administration. Its resources, combined with Cost Plus Drug Co.’s emphasis on drug pricing transparency, will allow the two to make strides in redefining “transparency in the healthcare sector, where opaque pricing models have been a major pain point for employers and their workforce,” according to the news release.
“At Cost Plus Drugs, we are committed to revolutionizing the pharmaceutical landscape through transparent drug pricing, and working with PCA Rx aligns seamlessly with our mission,” Alex Oshmyansky, MD, PhD, CEO of Mark Cuban Cost Plus Drug Co. stated. “Together, we are ensuring affordability, accessibility, and clarity in medication costs, empowering individuals to make informed choices about their health and well-being.”
